There is an association between nonalcoholic fatty liver disease (NAFLD) and the polycystic ovary syndrome (PCOS). Marine-derived omega-3 fatty acids have favorable effects on cardiovascular risk and could reduce liver fat in NAFLD.
P
olycystic ovary syndrome (PCOS) is the most common endocrine disorder affecting women of reproductive age and is characterized by hyperandrogenism, menstrual disturbance and polycystic ovaries on ultrasound (1) . PCOS is associated with multiple cardiovascular risk factors, including insulin resistance, central obesity, hypertension, impaired glucose tolerance, type 2 diabetes, and the metabolic syndrome (2) . PCOS is also associated with nontraditional markers of cardiovascular risk, such as inflammation, thrombosis, oxidative stress, sleep apnea, endothelial dysfunction, and arterial stiffness (3) .
More recently, a link between PCOS and nonalcoholic fatty liver disease (NAFLD) has been demonstrated (4 -8) .
The prevalence of NAFLD in women with PCOS may be as high as 40 -55% (6, 7), whereas a recent study found that the majority of women with NAFLD had evidence of PCOS (8) . NAFLD is characterized by increased hepatic storage of triglycerides and carries a risk of progression to hepatic cirrhosis and liver failure (9) . Like PCOS, NAFLD has a strong association with insulin resistance, the metabolic syndrome, and obesity (10) . NAFLD is also a powerful independent predictor of cardiovascular disease (11) .
The most common laboratory abnormality associated with NAFLD is an elevation of alanine aminotransferase (ALT), whereas imaging studies (ultrasound, computer tomography scanning, and magnetic resonance imaging) along with liver biopsy are used to confirm the diagnosis. Hepatic proton magnetic resonance spectroscopy (HMRS) is a well validated, noninvasive method for quantitatively assessing liver fat content, which correlates closely with liver histology (12, 13) .
Treatment options for NAFLD include weight loss measures, exercise, insulin sensitizers, lipid regulators, and specific hepatoprotectors such as antioxidants and antiinflammatory agents (14, 15) . Although reducing liver fat content has been associated with improvement in hepatic aminotransferases, liver histology, and imaging markers of hepatic steatosis, long-term data confirming that this translates into a prognostic advantage from the hepatic or cardiovascular perspective are lacking (15) .
Very few published studies have tested these interventions in the setting of PCOS. Animal studies of marine-derived omega-3 fatty acids have demonstrated beneficial effects in NAFLD (16) . Consistent with these data are the results of a small number of clinical studies demonstrating that supplementation with omega-3 fatty acids improves biochemical and ultrasonographic features of NAFLD (17) (18) (19) . Possible mechanisms of action of omega-3 fatty acids include inhibition of triglyceride synthesis, as well as antiinflammatory (20) and antioxidant (21) effects.
Our primary aim was to investigate whether dietary supplementation with omega-3 fatty acids in women with PCOS would decrease liver fat content. Our secondary aim was to assess the effects on cardiometabolic risk factors, such as blood pressure, plasma lipids, insulin resistance, and inflammation.
Subjects and Methods

Subjects
We recruited 25 women with PCOS, defined by clinical or biochemical hyperandrogenism, plus oligomenorrhea, with the exclusion of other etiologies (22, 23) . Subjects were recruited through advertising in local newspapers and from a preexisting database of clinic patients with known PCOS. All subjects were overweight/obese [body mass index (BMI) Ͼ25 kg/m 2 ]. Exclusion criteria included: smoking, age below 18 yr, postmenopausal, uncontrolled hypertension (blood pressure Ͼ160/100 mm Hg), preexisting fish oil supplementation, alcohol intake greater than 20 g/d, or pregnancy. Subjects were asked to maintain their usual dietary and alcohol intake throughout the study. Subjects with diabetes, abnormal cholesterol, or on treatment for these conditions remained eligible for the study, as were those taking a combined oral contraceptive pill (OCP). These subjects were included in the study to demonstrate that the beneficial effects of omega-3 fatty acids are evident in the setting of treatment with common medical interventions for PCOS, making the results of this study more relevant to clinical practice. All subjects provided written informed consent. The study was approved by the Ethics Committee of Royal Perth Hospital and was registered with ClinicalTrials.gov (registration no. NCT00620529).
Study design
The study was double-blinded with a randomized crossover design. Subjects were randomized to 4 g daily of omega-3 fatty acids (4 ϫ 1000-mg capsules of 56% docosahexaenoic acid and 27% eicosapentaenoic acid, Ocean Nutrition, Halifax, Nova Scotia, Canada), or control (4 ϫ 1000-mg capsules of olive oil containing 67% oleic acid; Cardinal Health Australia, Braeside, Victoria, Australia) for 8 wk, followed by an 8-wk washout period, and then the alternate supplement capsules for another 8 wk. Subjects were assessed clinically and biochemically at baseline and at the end of each intervention period. HMRS was performed only at the end of each intervention period.
Clinical assessment
All subjects had a detailed clinical assessment by an endocrinologist. Weight, height, and waist and hip measurements were recorded, from which BMI and waist:hip ratio were calculated. Supine resting blood pressure was measured with an automated blood pressure recorder (Dinamap, Critikon, FL) at 2-min intervals for 10 min, with the first reading deleted and the remaining readings averaged. All blood tests were carried out after a 12-h fast.
Biochemical assessment
Insulin, SHBG, LH, FSH, estradiol, and progesterone were measured with chemiluminescent immunometric assays using the Immulite 2000 system (Siemens Medical Solutions Diagnostics, Los Angeles, CA). Testosterone was assessed using solid phase RIA (Siemens Medical Solutions Diagnostics). Plasma glu-cose levels, total cholesterol, triglycerides, high-density lipoprotein (HDL), and ALT were measured by enzymatic methods using either the Hitachi 917 analyzer (Roche Diagnostics, Basel, Switzerland) or the Architect ci8200 system (Abbott Diagnostics, Wiesbaden, Germany). Low-density lipoprotein (LDL) cholesterol was calculated by the Friedewald formula (24). Nonesterified fatty acids (NEFA) were assayed with a Wako reagent using an enzymatic method (Novachem, Collingwood Victoria, Australia). Highly sensitive C-reactive protein (hs-CRP) was assessed immunochemically using a Dade Behring reagent (Dade Behring, Eschborn, Germany). The homeostasis model assessment insulin resistance index (HOMA-IR) was calculated as: [fasting glucose (mmol/liter) ϫ fasting insulin (mU/liter)]/22.5. The free androgen index was calculated as: [total testosterone (nmol/liter)/SHBG (nmol/liter)] ϫ 100.
HMRS
Single voxel (30 ϫ 30 ϫ 30 mm 3 ) proton spectra from the liver were acquired using a flexible surface coil and a 1.5-tesla magnetic resonance device (Sonata; Siemens Medical System, Erlangen, Germany), and voxels were positioned to avoid large vessels and bile ducts. A point resolved spectroscopy sequence was used, and two separate spectra were acquired for each study, both with breath hold: 1) repetition time 3000 msec and echo time 30 msec, four signal averages, no water suppression; 2) repetition time 1500 msec and echo time 30 msec, seven signal averages, with water suppression. Before acquisition of the proton spectra, a dummy measurement with the same parameters as in sequence 1 but without breath hold was performed for shimming. The manufacturer's HMRS processing software (Siemens Medical System) was used to obtain liver fat signal (S fat ) from the spectra with water suppression and liver water signal (S water ) from the spectra without water suppression. Hepatic fat percentage was calculated by dividing (100 times S fat ) by the sum of S fat and S water as previously described (25) .
Statistical analysis
Statistical analysis was performed using SPSS version 15.0 (SPSS Inc, Chicago, IL). Data are expressed as mean Ϯ SD, or geometric mean and 95% confidence interval (CI) for variables requiring logarithmic transformation. Treatment effects were analyzed by paired t tests and repeated measures ANOVA. Analyses were carried out in the whole group, as well as subgroups defined according to the presence (liver fat Ͼ5%, HLF group) or absence (liver fat Յ5%, NLF group) of hepatic steatosis while taking placebo. The liver fat percentage cutoff point of 5% was based on 95 percentile values for liver fat content using HMRS in a study of control subjects without risk factors for NAFLD by Browning et al. (26) . To test for crossover effect, an ANOVA repeated measures calculation was performed assessing the interaction between treatment sequence and liver fat content. Power calculations revealed that to detect a 2.5% difference in liver fat percentage as quantified by HMRS using a crossover study design, 18 subjects would need to enter the study. This assumed 90% power, 5% ␣ error, and a 3.7% SD for liver fat percentage (27) . Statistical significance was defined as P Յ 0.05.
Results
Subject characteristics at recruitment are shown in Table 1 . On average, subjects were obese, with central adiposity as reflected by an elevated waist:hip ratio [0.91 (0.08)]. The group as a whole was normotensive but had some evidence of insulin resistance [HOMA-IR, 3.08 (2.44)]. There were four subjects with known, preexisting impaired glucose tolerance, plus one subject with type 2 diabetes; all of these subjects were taking metformin. Two subjects had a history of hypertension and were both taking antihypertensive agents (irbesartan and ramipril). There were seven subjects taking the OCP. Study outcomes remained significant when these subjects were excluded from the analysis. Subjects ingested an average of 1.4 fish meals per week and 22.0 g alcohol per week. The HLF subjects (n ϭ 12) had significantly higher BMI, systolic blood pressure (SBP), triglycerides, NEFA, fasting insulin, and HOMA-IR levels compared with the NLF group (n ϭ 13). The effects of omega-3 fatty acids compared with placebo on outcome variables for the whole group are summarized in Table 2 . Omega-3 fatty acids were associated with a significant reduction in liver fat content, blood pressure, and triglycerides, but there was no significant effect on BMI, ALT, NEFA, insulin resistance, hs-CRP, or androgen status. Correlation analysis revealed a significant correlation between liver fat content and ALT, BMI, fasting glucose, fasting insulin, NEFA, and HOMA-IR (all P values Ͻ0.03). Table 3 shows changes in outcome variables with omega-3 fatty acids compared with placebo in the NLF and HLF groups. Omega-3 fatty acids in the HLF subjects were associated with a significant reduction in liver fat, triglycerides, fasting insulin, and HOMA-IR score compared with placebo. The NLF group had a significant reduction in SBP with omega-3 fatty acids, which was supported by a similar but nonsignificant trend toward a reduction in diastolic blood pressure (DBP), but there were no differences in liver fat levels, lipids, or parameters of glucose metabolism. There was a significant correlation between liver fat levels and HOMA-IR (P Ͻ 0.01) and free androgen index (P ϭ 0.04) in the HLF group, and no significant withingroup correlations in the NLF group.
Discussion
We demonstrate for the first time, in a randomized controlled study, that dietary supplementation with omega-3 fatty acids has a beneficial effect on liver fat content in women with PCOS. The effect of omega-3 fatty acids on liver fat was seen primarily in women with hepatic steatosis, defined as liver fat content of at least 5% (26) . Omega-3 fatty acids were also associated with reduced plasma triglycerides and blood pressure in this study. Our data therefore suggest that the known cardiometabolic benefits of omega-3 fatty acids may also apply to women with PCOS.
There is a strong association between NAFLD and PCOS (6 -8), consistent with the central role of insulin resistance in the pathogenesis of both conditions. NAFLD is characterized by accumulation of triglycerides in liver storage pools as a result of deranged peripheral and intrahepatic lipid metabolism. Pathogenic factors include increased peripheral lipolysis, resulting in greater uptake of NEFAs by the liver, together with increased synthesis and storage of triglycerides. Hyperinsulinemia promotes hepatic uptake of triglyceriderich lipoproteins and results in reduced production of very low-density lipoprotein (VLDL) and apolipoprotein B-100, contributing to the net gain in intrahepatic lipid content (28) . Increased delivery of NEFAs to the liver results in uncoupling of mitochondrial function with increased generation of reactive oxygen species. Mitochondrial reactive oxygen species then promote lipid peroxidation, which leads to hepatic inflammation, fibrosis, and apoptosis (29) . Omega-3 fatty acids reduce inflammation and oxidative stress and decrease hepatic triglyceride synthesis, which may explain the reduction in hepatic fat content seen with omega-3 fatty acids in the present study. The mechanisms by which omega-3 fatty acids alter hepatic lipid metabolism include the synthesis, metabolism, and clearance of lipids; they occur primarily via genomic pathways (30, 31) and are shown in Fig. 1 . Omega-3 fatty acids alter the transcription of hepatic genes involved in lipid metabolism such as peroxisome proliferator-activated receptor-␣, sterol regulatory element binding protein-1, and the carbohydrate regulatory element binding protein/Max-like factor X heterodimer (31) . The transcription products of these genes influence the synthesis, transport, and oxidation of fatty acids as well as aspects of intrahepatic glucose metabolism such as glucose transport and glycolysis. Omega-3 fatty acids also decrease postprandial lipemia and thereby reduce the uptake of exogenously derived triglycerides by the liver (32) . In addition, omega-3 fatty acids increase lipoprotein lipase activity, leading to increased triglyceride lipolysis and reduction in the plasma pool of triglycerides with reduced hepatic uptake from the circulation (33). Our study revealed no change in plasma NEFA concentrations, suggesting that the primary effects of omega-3 fatty acids were mediated via changes in intrahepatic lipid metabolism, rather than to decrease NEFA flux to liver, although formal tracer studies would be required to establish this notion. That hs-CRP was not significantly altered by omega-3 fatty acids suggests that a global antiinflammatory effect was not involved. Measurement of other molecules, such as TNF-␣ and IL-6, would be required to fully exclude the role of alterations in inflammatory signaling.
The findings of our study are consistent with the outcomes of the small number of previous studies examining the effects of omega-3 fatty acids on hepatic fat metabolism. Animal studies have demonstrated that activation of peroxisome proliferator-activated receptor-␣ secondary to increased dietary omega-3 fatty acids leads to a reduction in hepatic lipogenesis (34) . Consistent with these findings are three small clinical studies demonstrating that omega-3 fatty acids improve ultrasonographic and biochemical indices of NAFLD (17) (18) (19) .
In the present study, we also demonstrated an improvement in blood pressure, which is consistent with the recognized effects of omega-3 fatty acids. NLF subjects were more likely to experience blood pressure benefits with omega-3 fatty acids than HLF subjects, which may reflect the small sample size of this study. Previous studies have shown a reduction in 24-h ambulatory blood pressure and other cardiovascular endpoints such as heart rate variability and recovery, and endothelial function, with omega-3 fatty acids (35) . Mechanisms for the blood pressure-lowering effects of omega-3 fatty acids include enhancing the release of vasoactive substances, such as nitric oxide, thromboxane A2, and prostacyclin, as well as direct effects on cell membrane function (35) .
Although it is well accepted that blood pressure and triglycerides are predictors of cardiovascular disease, strong ep- idemiological data now exist linking NAFLD and long-term risk of adverse cardiovascular outcomes (36) . NAFLD is associated with the metabolic syndrome, a cluster of cardiovascular risk factors known to predict long-term cardiovascular events, and may be seen as an additional marker of cardiometabolic risk (36) . The improvement in liver fat content, along with factors such as plasma triglycerides, blood pressure, and possibly insulin resistance, in women with PCOS seen in the current study indicates that omega-3 fatty acids may not only be a valuable management option for these conditions but also may have the additional benefit of reducing overall cardiovascular risk in the setting of PCOS. The limitations of this study are primarily related to small sample size, and confirmation of these findings in a larger study group would be desirable. The present study showed the greatest benefits in subjects with increased hepatic fat levels-further studies focusing specifically on this subgroup would therefore be useful. In addition, the current study included only obese women with PCOS. Studies of the effects of omega-3 fatty acids in lean women with PCOS, who are known to have an increased risk of NAFLD (7) and an elevation of cardiovascular risk (37) , would also be worthwhile. This study focused on hepatic steatosis, which may be seen as the first "hit" in the pathological spectrum of NAFLD. To assess whether omega-3 fatty acids reduce hepatic fibrosis and cirrhosis, long-term intervention studies with liver histology are required. A limitation of imaging modalities, including HMRS, in the setting of NAFLD is their inability to distinguish simple steatosis from steatohepatitis. Future studies using the dual endpoints of HMRS and liver biopsy would therefore be useful in providing additional insight into the relationship between hepatic imaging and histopathology. The crossover study design also has its limitations, with the potential for a carryover effect altering outcomes. However, we found no evidence of a carryover effect when the relationship between treatment sequence and liver fat content was examined statistically. Finally, the effects of omega-3 fatty acids in PCOS are likely to be dose-related, meaning the results of the current study may not be applicable to lower doses of omega-3 fatty acids or to a simple increase in dietary fish intake.
Conclusions
This study demonstrates beneficial effects of omega-3 fatty acids on NAFLD and additional markers of cardiometabolic risk in young, obese women with PCOS. The long-term cardioprotective effects of omega-3 fatty acids are now well accepted, and the findings of the current study suggest that women with PCOS are also likely to experience these benefits, although confirmation of these results in larger studies is required. In the interim, management of women with PCOS should be guided by current recommendations that incorporate omega-3 fatty acids as part of a multifaceted approach to managing cardiometabolic risk.
